Medtronic (NYSE:MDT) Announces Quarterly Earnings Results, Beats Expectations By $0.01 EPS

Medtronic (NYSE:MDT) issued its earnings results on Wednesday. The medical technology company reported $1.55 EPS for the quarter, topping analysts’ consensus estimates of $1.54 by $0.01, FiscalAI reports. Medtronic had a net margin of 13.20% and a return on equity of 14.61%. The company had revenue of $9.81 billion for the quarter, compared to the consensus estimate of $9.62 billion. During the same period in the previous year, the firm earned $1.62 earnings per share. Medtronic’s quarterly revenue was up 9.9% compared to the same quarter last year. Medtronic updated its FY 2027 guidance to 5.900-6.000 EPS.

Here are the key takeaways from Medtronic’s conference call:

• Medtronic reported a strong fiscal 2026 finish, with Q4 revenue of $9.8 billion (+9.9% reported, +6.6% organic) and full-year revenue of $36.4 billion (+8.4% reported, +5.8% organic), the company’s best top-line performance in 10 years. Adjusted EPS also came in ahead of expectations at $1.55 in Q4 and $5.53 for the full year.
• Cardiac Ablation Solutions remained a standout growth engine, with 78% worldwide growth and continued rapid adoption of PFA/Affera, including a 40% sequential increase in the U.S. installed base. Management said the business is still early in its ramp and is on track to reach a $2 billion annualized revenue run rate in Q1 FY2027.
• Symplicity is gaining traction in hypertension treatment, with physician access expanding, prior authorization approvals improving, and weekly procedure volumes doubling since reimbursement coverage changed. Medtronic said the franchise is now annualizing at $100 million and highlighted long-term clinical data supporting its differentiated position.
• The company’s outlook for fiscal 2027 organic revenue growth is 6.75%–7.25%, supported by ongoing momentum in cardiovascular, neuroscience, MedSurg, and MiniMed, plus an extra selling week in Q1. Management also signaled continued investment in M&A and commercialization while expecting tariffs and mix to pressure margins.
• Medtronic continues to reshape the portfolio, completing the MiniMed IPO and announcing/investing in several tuck-in deals, including CathWorks, Scientia, SPR Therapeutics, Beluga Medical, CardioACC, and others. The company said these moves are meant to strengthen leadership positions and expand exposure to faster-growing adjacencies over time.

Medtronic Stock Up 5.1%

Shares of NYSE:MDT opened at $81.95 on Friday. Medtronic has a 1-year low of $73.31 and a 1-year high of $106.33. The company has a debt-to-equity ratio of 0.57, a current ratio of 2.54 and a quick ratio of 1.87. The stock has a market cap of $105.22 billion, a P/E ratio of 21.97, a P/E/G ratio of 1.89 and a beta of 0.58. The firm has a fifty day moving average price of $81.58 and a 200 day moving average price of $92.11.

Medtronic Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, July 17th. Investors of record on Friday, June 26th will be given a $0.72 dividend. This is a positive change from Medtronic’s previous quarterly dividend of $0.71. The ex-dividend date is Friday, June 26th. This represents a $2.88 annualized dividend and a yield of 3.5%. Medtronic’s payout ratio is currently 79.11%.

Medtronic News Roundup

Here are the key news stories impacting Medtronic this week:

• Positive Sentiment: Medtronic beat fiscal Q4 revenue expectations with $9.81 billion in sales and posted EPS of $1.55, while management highlighted the strongest annual revenue growth in a decade. Medtronic PLC (MDT) Q4 2026 Earnings Call Highlights: Record Revenue Growth and Strategic …
• Positive Sentiment: The company raised its quarterly dividend to $0.72 per share, signaling confidence in cash flow and shareholder returns. Medtronic submits 510(k) filings to expand Hugo™ robotic-assisted surgery system into general and gynecologic specialties in the United States
• Positive Sentiment: Analysts pointed to accelerating organic growth and the Hugo robotic surgery rollout as reasons for optimism; BTIG upgraded Medtronic to Buy, and several other firms reiterated bullish or constructive ratings. Wall Street May Be Mispricing Medtronic, Analyst Says
• Neutral Sentiment: Medtronic’s surgical expansion is progressing, with new FDA filings and clearances for Hugo RAS in general and gynecologic procedures, which supports the long-term growth story but is still early-stage. Medtronic Balances Hugo Robotics Expansion With Ongoing Cardiovascular Device Recalls
• Neutral Sentiment: Several Wall Street firms reduced price targets after earnings, reflecting caution around margins and FY2027 guidance, though most still kept neutral-to-positive ratings. How To Earn $500 A Month From Medtronic Stock After Q4 Earnings
• Negative Sentiment: Medtronic’s FY2027 EPS guidance of $5.90 to $6.00 came in below the consensus view, and some analysts cited tariff and cost pressures as headwinds. Medtronic (MDT) Climbs 5.7% on Stellar Q4

Analyst Ratings Changes

Several analysts have recently commented on the stock. Argus reduced their price target on shares of Medtronic from $125.00 to $115.00 and set a “buy” rating on the stock in a research report on Monday, April 6th. Wells Fargo & Company reduced their target price on Medtronic from $114.00 to $102.00 and set an “overweight” rating on the stock in a research report on Thursday. Evercore set a $106.00 price objective on Medtronic and gave the stock an “outperform” rating in a research report on Thursday, April 9th. Sanford C. Bernstein restated an “outperform” rating and issued a $97.00 price objective on shares of Medtronic in a report on Thursday. Finally, Daiwa Securities Group lowered their target price on Medtronic from $117.00 to $115.00 and set a “buy” rating for the company in a report on Friday, February 27th. Sixteen investment analysts have rated the stock with a Buy rating and eleven have given a Hold rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $98.70.

Institutional Trading of Medtronic

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Quadrant Capital Group LLC raised its stake in shares of Medtronic by 0.3% in the 4th quarter. Quadrant Capital Group LLC now owns 32,477 shares of the medical technology company’s stock valued at $3,120,000 after acquiring an additional 101 shares in the last quarter. Rossby Financial LCC raised its position in shares of Medtronic by 5.1% in the fourth quarter. Rossby Financial LCC now owns 2,193 shares of the medical technology company’s stock valued at $211,000 after purchasing an additional 107 shares during the period. Wealthspire Retirement LLC boosted its holdings in shares of Medtronic by 5.0% during the 4th quarter. Wealthspire Retirement LLC now owns 2,410 shares of the medical technology company’s stock worth $232,000 after buying an additional 114 shares during the period. Mitchell Mcleod Pugh & Williams Inc. increased its position in Medtronic by 2.0% during the fourth quarter. Mitchell Mcleod Pugh & Williams Inc. now owns 6,043 shares of the medical technology company’s stock worth $622,000 after acquiring an additional 117 shares during the period. Finally, Florida Financial Advisors LLC lifted its position in Medtronic by 4.8% in the second quarter. Florida Financial Advisors LLC now owns 2,683 shares of the medical technology company’s stock worth $234,000 after purchasing an additional 122 shares during the period. 82.06% of the stock is owned by hedge funds and other institutional investors.

About Medtronic

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).